lips241b-T4

Tabla 4: Resumen de nivel de evidencia y

grado de recomendación de los artículos revisados.

Referencia

ECA

Nivel de

evidencia

Grado de

recomendación

Muñoz FM, Swamy GK, Hickman SP, Agrawal S, Piedra PA, Glenn GM, et al. Safety and immunogenicity of a respiratory syncytial virus fusion (F) protein nanoparticle vaccine in healthy third-trimester pregnant women and their infants. J Infect Dis. 2019; 220 (11): 1802-1815.

Sí

1A

B

Madhi SA, Polack FP, Piedra PA, Muñoz FM, Trenholme AA, Simoes EAF, et al. Respiratory syncytial virus vaccination during pregnancy and effects in infants. N Engl J Med. 2020; 383 (5): 426-439.

Sí

1A

A

Simoes EAF, Center KJ, Tita ATN, Swanson KA, Radley D, Houghton J, et al. Prefusion F protein-based respiratory syncytial virus immunization in pregnancy. N Engl J Med. 2022; 386 (17): 1615-1626.

Sí

1A

A

Dieussaert I, Hyung KJ, Luik S, Seidl C, Pu W, Stegmann JU, et al. RSV Prefusion F protein-based maternal vaccine - Preterm birth and other outcomes. N Engl J Med. 2024; 390 (11): 1009-1021.

Sí

1A

B

Kampmann B, Madhi SA, Munjal I, Simoes EAF, Pahud BA, Llapur C, et al. Bivalent prefusion F vaccine in pregnancy to prevent RSV illness in infants. N Engl J Med. 2023; 388 (16): 1451-1464.

Sí

1A

A

Bebia Z, Reyes O, Jeanfreau R, Kantele A, De Leon RG, Sanchez MG, et al. Safety and immunogenicity of an investigational respiratory syncytial virus vaccine (RSVPreF3) in mothers and their infants: a phase 2 randomized trial. J Infect Dis. 2023; 228 (3): 299-310.

Sí

1A

A

ECA = ensayo clínico aleatorizado.

Tabla 4: Resumen de nivel de evidencia y grado de recomendación de los artículos revisados.
Referencia	ECA	Nivel de evidencia	Grado de recomendación
Muñoz FM, Swamy GK, Hickman SP, Agrawal S, Piedra PA, Glenn GM, et al. Safety and immunogenicity of a respiratory syncytial virus fusion (F) protein nanoparticle vaccine in healthy third-trimester pregnant women and their infants. J Infect Dis. 2019; 220 (11): 1802-1815.	Sí	1A	B
Madhi SA, Polack FP, Piedra PA, Muñoz FM, Trenholme AA, Simoes EAF, et al. Respiratory syncytial virus vaccination during pregnancy and effects in infants. N Engl J Med. 2020; 383 (5): 426-439.	Sí	1A	A
Simoes EAF, Center KJ, Tita ATN, Swanson KA, Radley D, Houghton J, et al. Prefusion F protein-based respiratory syncytial virus immunization in pregnancy. N Engl J Med. 2022; 386 (17): 1615-1626.	Sí	1A	A
Dieussaert I, Hyung KJ, Luik S, Seidl C, Pu W, Stegmann JU, et al. RSV Prefusion F protein-based maternal vaccine - Preterm birth and other outcomes. N Engl J Med. 2024; 390 (11): 1009-1021.	Sí	1A	B
Kampmann B, Madhi SA, Munjal I, Simoes EAF, Pahud BA, Llapur C, et al. Bivalent prefusion F vaccine in pregnancy to prevent RSV illness in infants. N Engl J Med. 2023; 388 (16): 1451-1464.	Sí	1A	A
Bebia Z, Reyes O, Jeanfreau R, Kantele A, De Leon RG, Sanchez MG, et al. Safety and immunogenicity of an investigational respiratory syncytial virus vaccine (RSVPreF3) in mothers and their infants: a phase 2 randomized trial. J Infect Dis. 2023; 228 (3): 299-310.	Sí	1A	A
ECA = ensayo clínico aleatorizado.